chart, page-979

First 979 Last

Share
Profile

Follow
Yeoda

549 Posts.

4

14/12/20

23:50

Post #: 49574150
Share

Originally posted by Esquatcho: ↑

OK, so Im reassessing my position. Do I remember right that they said they would have 60% GM on each unit sold at $300? So on that basis, are we losing $20 per unit made now at $100 instead?

Lets say each unit is break-even though....

Based on $9.95/mth, 85% retention and 85% GM, that means each unit gets $86 Gross Profit per year.

For a MC of ~$100M, if we assume PE of 20, we need NPAT of $5M pa. say that means $7M EBITDA and then maybe $10M of Gross Profit. That means we need about ~110k units sold to justify the current MC.

Is there anything Im missing here? Too much on sales overheads?

So what does 110k units sold look like? Well, 460k kids with asthma in Australia. 25% of the market would do it. So how fast can RSH grow to that market share? Is that a reasonable short term growth aspiration?

The upside? Well, the US has more like $5.5M kids with Asthma. Even 10% of that market would mean this is closer to a billion $ business and a Disallowed.

The question is how far would that be away?

Expand

only a PE of 20 for a company like this?
surely you would be using PE of at least 40-60 when especially when the plan is to expand into Europe and America?
The share market is ridiculous with valuations these days, just look at the likes of afterpay.. what would their PE?

RSH Price at posting: 14.0¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

PL3

Patagonia looks to raise $2.15M for South American exploration and development

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

There are more pages in this discussion • 1,104 more messages in this thread...

First 979 Last

Add RSH (ASX) to my watchlist

(20min delay)
Last 2.6¢		Change -0.001(3.70%)		Mkt cap ! $29.80M

Open	High	Low	Value	Volume
2.7¢	2.7¢	2.6¢	$2.391K	89.1K

Buyers (Bids)

No.	Vol.	Price($)
2	594479	2.6¢

Sellers (Offers)

Price($)	Vol.	No.
3.0¢	60000	2

View Market Depth

No.	Vol.	Price($)
2	594479	0.026
1	632000	0.024
1	130000	0.022
4	463245	0.021
3	580000	0.020

Price($)	Vol.	No.
0.030	60000	2
0.031	133599	2
0.032	250000	4
0.033	365000	1
0.034	1000000	1

Last trade - 16.10pm 09/07/2024 (20 minute delay)

RSH (ASX) Chart

chart, page-979

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

chart, page-979

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News